| Year |
Citation |
Score |
| 2020 |
Tajzler C, Tanguay S, Mallick R, Ahrens B, Ly TL, Breau RH, Basappa NS, Kapoor A, Heng DYC, Pouliot F, Finelli A, Lavallée LT, So AI, Drachenberg DE, Soulières D, et al. Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: E499-E506. PMID 33275557 DOI: 10.5489/Cuaj.6716 |
0.393 |
|
| 2020 |
Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, Kolinsky M, Malone S, Morash C, Niazi T, Noonan KL, Ong M, Pouliot F, Shayegan B, So AI, et al. Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 32853135 DOI: 10.5489/Cuaj.6779 |
0.394 |
|
| 2020 |
Asselin C, Finelli A, Breau RH, Mallick R, Kapoor A, Rendon RA, Tanguay S, Pouliot F, Fairey A, Lavallée LT, Bladou F, Kawakami J, So AI, Richard PO. Does renal tumor biopsies for small renal carcinoma increase the risk of upstaging on final surgery pathology report and the risk of recurrence? Urologic Oncology. PMID 32693974 DOI: 10.1016/J.Urolonc.2020.06.001 |
0.337 |
|
| 2020 |
Ghavimi S, Saarela O, Pouliot F, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lavallee L, Lacombe L, Fairey A, Jewett M, Liu Z, Tanguay S, Black PC. Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. World Journal of Urology. PMID 32656670 DOI: 10.1007/S00345-020-03349-Y |
0.339 |
|
| 2020 |
Shiff B, Breau RH, Patel P, Mallick R, Tanguay S, So A, Lavallée L, Moore R, Rendon R, Kapoor A, Pouliot F, Finelli A, Bhindi B, Lattouf JB, Basappa N, et al. Impact of Time-To-Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. The Journal of Urology. 101097JU000000000000. PMID 32614274 DOI: 10.1097/Ju.0000000000001230 |
0.338 |
|
| 2020 |
Kokorovic A, So AI, Hotte SJ, Black PC, Danielson B, Emmenegger U, Finelli A, Niazi T, Pouliot F, Shayegan B, Sridhar S, Vigneault E, Loblaw A, Rendon R. A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 32374715 DOI: 10.5489/Cuaj.6667 |
0.372 |
|
| 2020 |
Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I, Klotz L. Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32096678 DOI: 10.1097/Ju.0000000000000809 |
0.379 |
|
| 2020 |
So AI, Chi KN, Danielson B, Fleshner NE, Kapoor A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar S, Vigneault E, Saad F. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: 17-23. PMID 31999544 DOI: 10.5489/Cuaj.6384 |
0.396 |
|
| 2020 |
Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallée É, Bergeron M, Brisson H, Champagne A, Neveu B, Lacombe D, Beauregard JM, Buteau FA, Riopel J, Pouliot F. GLUT1 expression in high-risk prostate cancer: correlation with F-FDG-PET/CT and clinical outcome. Prostate Cancer and Prostatic Diseases. PMID 31932660 DOI: 10.1200/Jco.2020.38.6_Suppl.291 |
0.329 |
|
| 2020 |
Yu EY, Laidley D, Pouliot F, Probst S, Saad F, Sabbagh R, Sartor AO. A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps260 |
0.396 |
|
| 2020 |
Pouliot F, Carroll P, Probst S, Pienta KJ, Rowe SP, Saperstein L, Siegel B, Patnaik A, Preston MA, Alva AS, Gorin MA, Morris MJ. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal of Clinical Oncology. 38: 9-9. DOI: 10.1200/Jco.2020.38.6_Suppl.9 |
0.363 |
|
| 2020 |
Zhang H, Basappa NS, Joy I, Ghosh S, Lalani AA, Hansen AR, Heng DYC, Castonguay V, Kollmannsberger CK, Winquist E, Wood L, Bjarnason GA, Breau RH, Pouliot F, Kapoor A, et al. Real-world evidence of cabozantinib in metastatic renal-cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 38: 682-682. DOI: 10.1200/Jco.2020.38.6_Suppl.682 |
0.382 |
|
| 2020 |
Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Graham J, Soulieres D, Hansen AR, Lalani AA, Castonguay V, Reaume MN, Bjarnason GA, Breau RH, Pouliot F, Kapoor A, et al. Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis). Journal of Clinical Oncology. 38: 633-633. DOI: 10.1200/Jco.2020.38.6_Suppl.633 |
0.354 |
|
| 2020 |
Hotte SJ, Finelli A, Chi KN, Canil CM, Fleshner N, Kapoor A, Kolinsky MP, Malone S, Morash C, Niazi T, Noonan K, Ong M, Pouliot F, Shayegan B, So A, et al. Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians. Journal of Clinical Oncology. 38: 29-29. DOI: 10.1200/Jco.2020.38.6_Suppl.29 |
0.392 |
|
| 2020 |
Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Levesque E, Klotz L, Guillemette C. Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy. Journal of Clinical Oncology. 38: 148-148. DOI: 10.1200/Jco.2020.38.6_Suppl.148 |
0.389 |
|
| 2020 |
Morris MJ, Carroll PR, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage K, Piert M, Iagaru A, Pollard JH, Wong V, Jensen JD, Stambler N, et al. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). Journal of Clinical Oncology. 38: 5501-5501. DOI: 10.1200/Jco.2020.38.15_Suppl.5501 |
0.359 |
|
| 2020 |
Plimack ER, Rini BI, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulieres D, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Journal of Clinical Oncology. 38: 5001-5001. DOI: 10.1200/Jco.2020.38.15_Suppl.5001 |
0.341 |
|
| 2020 |
Champagne A, Jain P, Neveu B, Pouliot F. Abstract 2015: A transcriptionally enhanced biosensor to detect and monitor biopsy-dissociated primary prostate cancer single cell drug responses by bioluminescence microscopy Clinical Trials. DOI: 10.1158/1538-7445.Am2020-2015 |
0.381 |
|
| 2020 |
Gorin MA, Siegel BA, Rowe SP, Saperstein L, Pouliot F, Josephson DY, Wong JYC, Pantel AR, Cho S, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, et al. Lba02-12 A Multicenter Phase 3 Study Of Psma-Targeted 18F-Dcfpyl Pet/Ct In Men With Biochemically Recurrent Prostate Cancer: Results From The Condor Trial The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000958.012 |
0.354 |
|
| 2020 |
Sprenkle P, Carroll P, Probst S, Gorin MA, Rowe SP, Pienta KJ, Pouliot F, Patnaik A, Preston MA, Alva A, Siegel BA, Morris MJ. Pd38-05 Clinical Utility Of Preoperative Psma-Targeted 18F-Dcfpyl Pet/Ct In Men With High-Risk Prostate Cancer: Diagnostic Performance Comparisons With Pelvic Ct Or Mri In The Osprey Prospective, Multi-Center Trial The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000917.05 |
0.377 |
|
| 2020 |
Kim S, Breau R, Mallick R, Kapoor A, Bhindi B, So A, Finelli A, Tanguay S, Pouliot F, Fairey A, Lavallee L, Maloni R, Rendon R. Mp50-05 How Well Does Renal Mass Size Measured By Ultrasound Correlate With Measurements Obtained By Ct, Mri Or Pathology? Analysis From The Canadian Kidney Cancer Information System The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000912.05 |
0.337 |
|
| 2019 |
Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L, Guillemette C. Extragonadal Steroids Contribute Significantly to the Androgen Receptor Activity and Castration Resistance Development in Recurrent Prostate Cancers after Primary Therapy. The Journal of Urology. 101097JU000000000000. PMID 31845837 DOI: 10.1097/Ju.0000000000000699 |
0.374 |
|
| 2019 |
Lavallée LT, McAlpine K, Kapoor A, Pouliot F, Mason R, Violette PD, Bansal RK, Richard PO, Karakiewicz PI, Bhindi B, Maloni R, Pautler S, Lattouf JB, Kassouf W, Tanguay S, et al. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 13: 377-383. PMID 31799919 DOI: 10.5489/Cuaj.6176 |
0.338 |
|
| 2019 |
Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, et al. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 13: 307-314. PMID 31603409 DOI: 10.5489/Cuaj.6136 |
0.404 |
|
| 2019 |
Joncas FH, Lucien F, Rouleau M, Morin F, Leong HS, Pouliot F, Fradet Y, Gilbert C, Toren P. Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. The Prostate. PMID 31475741 DOI: 10.1002/Pros.23901 |
0.363 |
|
| 2019 |
Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. European Urology Oncology. PMID 31411963 DOI: 10.1016/J.Euo.2019.01.009 |
0.382 |
|
| 2019 |
Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, ... ... Pouliot F, et al. Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 31378448 DOI: 10.1016/J.Clon.2019.07.010 |
0.331 |
|
| 2019 |
Wong ECL, Breau RH, Mallick R, Wood L, Pouliot F, Basappa NS, Tanguay S, Soulières D, So A, Heng D, Lavallée LT, Drachenberg D, Kapoor A. Renal cell carcinoma in the Canadian Indigenous population. Current Oncology (Toronto, Ont.). 26: e367-e371. PMID 31285681 DOI: 10.3747/Co.26.4707 |
0.327 |
|
| 2019 |
Nayan M, Jalali S, Kapoor A, Finelli A, So A, Rendon R, Breau RH, Lavallee LT, Tanguay S, Heng D, Kawakami J, Basappa NS, Bjarnason G, Pouliot F, Hamilton RJ. Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology. PMID 31285115 DOI: 10.1016/J.Urolonc.2019.06.006 |
0.337 |
|
| 2019 |
Wong ECL, Di Lena R, Breau RH, Pouliot F, Finelli A, Lavallée LT, So A, Tanguay S, Fairey A, Rendon R, Richard PO, Lattouf JB, Kawakami J, Mallick R, Kapoor A. Morphologic subtyping as a prognostic predictor for survival in papillary renal cell carcinoma: Type 1 vs. type 2. Urologic Oncology. PMID 31176614 DOI: 10.1016/J.Urolonc.2019.05.009 |
0.344 |
|
| 2019 |
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 30779529 DOI: 10.1056/Nejmoa1816714 |
0.351 |
|
| 2019 |
Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F, Bolduc S. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. Bmc Cancer. 19: 137. PMID 30744595 DOI: 10.1186/S12885-019-5353-6 |
0.382 |
|
| 2019 |
Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F. Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections. PMID 30673630 DOI: 10.1530/Ec-18-0476 |
0.301 |
|
| 2019 |
Jain P, Clermont PL, Desmeules F, Zoubeidi A, Neveu B, Pouliot F. Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells. International Journal of Molecular Sciences. 20. PMID 30626088 DOI: 10.3390/Ijms20010216 |
0.393 |
|
| 2019 |
Breau RH, Cagiannos I, Knoll G, Morash C, Cnossen S, Lavallée LT, Mallick R, Finelli A, Jewett M, Leibovich BC, Cook J, LeBel L, Kapoor A, Pouliot F, Izawa J, et al. Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. Bmj Open. 9: e025662. PMID 30610026 DOI: 10.1136/Bmjopen-2018-025662 |
0.326 |
|
| 2019 |
McDermott DF, Lee J, Ziobro M, Gafanov RA, Matveev VB, Suárez C, Donskov F, Pouliot F, Alekseev BY, Wiechno P, Tomczak P, Duran MAC, Shin SJ, Silverman RK, Perini RF, et al. First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B. Journal of Clinical Oncology. 37: 546-546. DOI: 10.1200/Jco.2019.37.7_Suppl.546 |
0.305 |
|
| 2019 |
Powles T, Plimack ER, Stus V, Gafanov RA, Hawkins RE, Nosov D, Pouliot F, Alekseev BY, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. Journal of Clinical Oncology. 37: 543-543. DOI: 10.1200/Jco.2019.37.7_Suppl.543 |
0.328 |
|
| 2019 |
Morris MJ, Pouliot F, Saperstein L, Rowe SP, Gorin MA, Josephson DY, Wong JYC, Carroll P, Lin T, Stambler N, Wong V, Jensen JD, Siegel BA. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5093 |
0.388 |
|
| 2019 |
Morris MJ, Durack JC, Alva AS, Vargas HA, Piert M, Pachynski RK, Pouliot F, Beauregard J, Preston MA, Choudhury AD, Saperstein L, Carroll P, Rowe SP, Pienta KJ, Lin T, et al. Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). Journal of Clinical Oncology. 37: 5012-5012. DOI: 10.1200/Jco.2019.37.15_Suppl.5012 |
0.356 |
|
| 2019 |
Tykodi SS, Donskov F, Lee J, Szczylik C, Malik J, Alekseev BY, Larkin JMG, Matveev VB, Gafanov R, Tomczak P, Geertsen PF, Wiechno PJ, Shin SJ, Pouliot F, Alonso-Gordoa T, et al. First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A. Journal of Clinical Oncology. 37: 4570-4570. DOI: 10.1200/Jco.2019.37.15_Suppl.4570 |
0.302 |
|
| 2019 |
Lee J, Ziobro M, Gafanov R, Matveev VB, Suarez C, Donskov F, Pouliot F, Alekseev BY, Wiechno PJ, Tomczak P, Climent MÁ, Shin SJ, Silverman RK, Perini RF, Schloss C, et al. KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC). Journal of Clinical Oncology. 37: 4569-4569. DOI: 10.1200/Jco.2019.37.15_Suppl.4569 |
0.33 |
|
| 2019 |
Kushnir I, Basappa NS, Ghosh S, Lalani AA, Soulieres D, Bjarnason GA, Wood L, Dawe D, Kollmannsberger CK, Heng DYC, Kapoor A, Hansen AR, Pouliot F, Reaume MN. Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Journal of Clinical Oncology. 37: 4516-4516. DOI: 10.1200/Jco.2019.37.15_Suppl.4516 |
0.393 |
|
| 2019 |
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Soulieres D, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Journal of Clinical Oncology. 37: 4500-4500. DOI: 10.1200/Jco.2019.37.15_Suppl.4500 |
0.325 |
|
| 2019 |
Ellis WJ, Donnelly BJ, Gorin MA, Pouliot F, Nguyen HG, Carroll PR, Scherr D, Probst S, Saperstein L, Fleshner N, Maroni P, Shah K, Stambler N, DiPippo VA, Strack T, et al. Pd60-11 A Phase 3 Study To Evaluate The Safety And Efficacy Of 99M Tc-Mip-1404 Spect/Ct Imaging To Detect Clinically Significant Prostate Cancer In Men With Biopsy Proven Low Grade Prostate Cancer Who Are Candidates For Active Surveillance (Prospect-As) The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557222.99762.6B |
0.384 |
|
| 2019 |
Gorin* MA, Pienta KJ, Siegel BA, Carroll P, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Rowe SP, Nichols M, Lin T, Strack T, et al. PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF
18
F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY) Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557215.99831.87 |
0.385 |
|
| 2019 |
Shiff B, Breau R, So A, Pouliot F, Kapoor A, Kawakami J, Lattouf J, Rendon R, Tanguay S, Mallick R, Bansal R. Mp42-07 Oncological Outcomes Of Patients With Sporadic, Non-Metastatic Renal Cell Carcinoma With Renal Vein Or Inferior Vena Cava Tumor Thrombus The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556210.51056.A3 |
0.354 |
|
| 2019 |
Cheung* D, Richard P, Magee D, Lavallée L, Pouliot F, Komisarenko M, Martin L, Lattouf J, Alibhai S, Krahn M, Finelli A. MP14-04 RENAL BIOPSY - WHEN WILL IT CHANGE MANAGEMENT? Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555300.24108.86 |
0.315 |
|
| 2019 |
Szabados B, Ruiz MD, Grant M, Liu W, Butters T, Pouliot F, Nosov D, Rini B, Powles T. Clinical outcomes of patients with metastatic renal cell carcinoma receiving subsequent therapy after progression on front-line immune-VEGF TKI combination therapy European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)34676-7 |
0.333 |
|
| 2019 |
Vigneault E, Carignan D, Pouliot F, Martin A, Foster W, Lavallée M, Lacroix F, Aubin S, Després P, Beaulieu L, Beauregard J. Feasibility of Intraprostatic Prostate Cancer Imaging with FCH-PET/CT for Preoperative Planning of Image-Guided HDR Brachytherapy Brachytherapy. 18. DOI: 10.1016/J.Brachy.2019.04.150 |
0.338 |
|
| 2018 |
Donskov F, McDermott DF, Lee JL, Szczylik C, Malik J, Alekseev BY, Larkin JMG, Matveev VB, Airatovich Gafanov R, Tomczak P, Tykodi SS, Geertsen PF, Wiechno P, Shin SJ, Pouliot F, et al. KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii307. PMID 32136713 DOI: 10.1093/Annonc/Mdy283.080 |
0.343 |
|
| 2018 |
Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond GR, Chua SS, Ho B, Johnston E, Pouliot F, Scott A. A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30442757 DOI: 10.2967/Jnumed.118.220103 |
0.32 |
|
| 2018 |
Saad F, Pouliot F, Danielson B, Catton C, Kapoor A. Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 12: E415-E420. PMID 30227914 DOI: 10.5489/Cuaj.5154 |
0.32 |
|
| 2018 |
Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH. Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 12: 231-238. PMID 30139427 DOI: 10.5489/Cuaj.5462 |
0.349 |
|
| 2018 |
Toren P, Hoffman A, Ding K, Joncas FH, Turcotte V, Caron P, Pouliot F, Fradet Y, Levesque E, Guillemette C, Klotz LH. Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30021911 DOI: 10.1158/1078-0432.Ccr-18-1187 |
0.401 |
|
| 2018 |
Ringuette-Goulet C, Bolduc S, Pouliot F. Modeling human bladder cancer. World Journal of Urology. PMID 29948049 DOI: 10.1007/S00345-018-2369-5 |
0.348 |
|
| 2018 |
Arsenault F, Beauregard JM, Pouliot F. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Current Opinion in Supportive and Palliative Care. PMID 29939893 DOI: 10.1097/Spc.0000000000000357 |
0.37 |
|
| 2018 |
Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, ... ... Pouliot F, et al. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 12: 173-180. PMID 29877179 DOI: 10.5489/Cuaj.5187 |
0.389 |
|
| 2018 |
Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, Finelli A. Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? The Journal of Urology. PMID 29653161 DOI: 10.1016/J.Juro.2018.04.015 |
0.337 |
|
| 2018 |
R Goulet C, Bernard G, Tremblay S, Chabaud S, Bolduc S, Pouliot F. Exosomes Induce Fibroblast Differentiation into Cancer-associated Fibroblasts through TGFβ Signaling. Molecular Cancer Research : McR. PMID 29636362 DOI: 10.1158/1541-7786.Mcr-17-0784 |
0.395 |
|
| 2018 |
Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F. Increased Prostate Cancer Glucose Metabolism Detected byF-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus. PMID 29609897 DOI: 10.1016/J.Euf.2018.03.008 |
0.366 |
|
| 2018 |
Kushnir I, Kirk L, Mallick R, Kim R, Graham GE, Breau RH, Lattouf J, Violette P, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, ... ... Pouliot F, et al. Application of Canadian hereditary renal cell carcinoma risk criteria to a population database. Journal of Clinical Oncology. 36: 621-621. DOI: 10.1200/Jco.2018.36.6_Suppl.621 |
0.316 |
|
| 2018 |
Morris MJ, Carroll P, Probst S, Pouliot F, Saperstein L, Siegel BA, Alva AS, Preston MA, Patnaik A, Gorin MA, Durack JC, Nichols M, Lin T, Strack T, DiPippo VA, et al. A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps5092 |
0.385 |
|
| 2018 |
Toren P, Hoffman A, Ding K, Joncas F, Pouliot F, Fradet Y, Lévesque É, Guillemette C, Klotz L. Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-A072 |
0.394 |
|
| 2018 |
Lavallee E, Bergeron M, Buteau F, Duchesnay N, Blouin A, Fradet Y, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Beauregard J, Pouliot F. Increased prostate cancer glucose metabolism detected by FDG-PET/CT in localised Gleason 8-10 prostate cancers identifies very high-risk patients for early recurrence and resistance to castration European Urology Supplements. 17: e1510. DOI: 10.1016/S1569-9056(18)31890-6 |
0.379 |
|
| 2018 |
Richard PO, Lavallée L, Pouliot F, Martin L, Komisarenko M, Latouff J, Finelli A. MP28-04 DO HIGH-VOLUME RENAL TUMOR BIOPSY CENTERS HAVE LOWER RATES OF BENIGN HISTOLOGY FOLLOWING NEPHRECTOMY FOR SMALL RENAL MASSES? Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.904 |
0.327 |
|
| 2018 |
Kokorovic A, Breau R, Finelli A, Tanguay S, Kapoor A, Kawakami J, Fairey A, So A, Drachenberg D, Lavallée LT, Lattouf J, Pouliot F, Mallick R, Rendon RA. Pd12-07 Predictors Of Pathologically Node Positive Disease In Patients Undergoing Retroperitoneal Lymph Node Dissection (Rplnd) For Renal Cell Carcinoma (Rcc): Results From The Canadian Kidney Cancer Collaboration The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.643 |
0.32 |
|
| 2017 |
Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y. Prognostic value of urinary PCA3 during active surveillance of low-risk prostate cancer in patients receiving 5α-reductase inhibitors. Bju International. PMID 28972698 DOI: 10.1111/Bju.14041 |
0.378 |
|
| 2017 |
Ringuette Goulet C, Bernard G, Chabaud S, Couture A, Langlois A, Neveu B, Pouliot F, Bolduc S. Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. Biomaterials. 145: 233-241. PMID 28888113 DOI: 10.1016/J.Biomaterials.2017.08.041 |
0.342 |
|
| 2017 |
Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, et al. Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: 232-237. PMID 28798821 DOI: 10.5489/Cuaj.4397 |
0.369 |
|
| 2017 |
Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus. PMID 28753860 DOI: 10.1016/J.Euf.2017.02.007 |
0.36 |
|
| 2017 |
Shayegan B, Pouliot F, So A, Fernandes J, Macri J. Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: 204-209. PMID 28652880 DOI: 10.5489/Cuaj.4539 |
0.359 |
|
| 2017 |
Basappa N, Pouliot F. New research in kidney cancer, ASCO-GU 2017. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: S163-S165. PMID 28616120 DOI: 10.5489/Cuaj.4607 |
0.357 |
|
| 2017 |
Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F. Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: E62-E63. PMID 28443152 DOI: 10.5489/Cuaj.4494 |
0.39 |
|
| 2017 |
Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F. Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: 16-23. PMID 28443139 DOI: 10.5489/Cuaj.4303 |
0.383 |
|
| 2017 |
Patel P, Nayak JG, Liu Z, Saarela O, Jewett M, Rendon RA, Kapoor A, Black P, Tanguay S, Kawakami J, Moore R, Breau RH, Morash C, Pouliot F, Drachenberg D. A multi-centered, propensity matched analysis comparing laparoscopic and open surgery for pT3a renal cell carcinoma. Journal of Endourology. PMID 28381117 DOI: 10.1089/End.2016.0787 |
0.327 |
|
| 2017 |
Kenmogne LC, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F, Poirier D. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models. Plos One. 12: e0171871. PMID 28182747 DOI: 10.1371/Journal.Pone.0171871 |
0.339 |
|
| 2017 |
Morin F, Beauregard J, Bergeron M, Nguilé-Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F. Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy. Journal of Clinical Oncology. 35: e590-e590. DOI: 10.1200/Jco.2017.35.6_Suppl.E590 |
0.344 |
|
| 2017 |
Velot L, Levesque D, Boisvert F, Bisson N, Pouliot F. Abstract 220: Proteomic identification of therapeutics targets for Enzalutamide resistance in Castration Resistant Prostate Cancer Cancer Research. 77: 220-220. DOI: 10.1158/1538-7445.Am2017-220 |
0.338 |
|
| 2016 |
Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F. Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens. Scientific Reports. 6: 33968. PMID 27678181 DOI: 10.1038/Srep33968 |
0.328 |
|
| 2015 |
Neveu B, Jain P, Têtu B, Wu L, Fradet Y, Pouliot F. A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer. Oncotarget. PMID 26594800 DOI: 10.18632/Oncotarget.6360 |
0.397 |
|
| 2015 |
Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 15: 2. PMID 25889163 DOI: 10.1186/S40644-015-0038-0 |
0.308 |
|
| 2015 |
Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Research. 75: 950-62. PMID 25736687 DOI: 10.1158/0008-5472.Can-14-0992 |
0.39 |
|
| 2015 |
Bessede T, Bigot P, Bernhard JC, Pignot G, Boulière F, Verhoest G, Crépel M, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Albouy B, Pouliot F, et al. Are warm ischemia and ischemia time still predictive factors of poor renal function after partial nephrectomy in the setting of elective indication? World Journal of Urology. 33: 11-5. PMID 24700310 DOI: 10.1007/S00345-014-1292-7 |
0.304 |
|
| 2015 |
Jain P, Neveu B, Fradet Y, Pouliot F. Abstract 206: Development of a molecular imaging system based on the transcriptional activity of the DD3/PCA3 non-coding RNA for imaging specifically the prostate cancer cells Cancer Research. 75: 206-206. DOI: 10.1158/1538-7445.Am2015-206 |
0.397 |
|
| 2015 |
Jain P, Neveu B, Fradet Y, Pouliot F. Mp61-13 Development Of A Molecular Imaging System Based On The Transcriptional Activity Of The Dd3/Pca3 Non-Coding Rna For Imaging Specifically The Prostate Cancer Cells The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2194 |
0.342 |
|
| 2014 |
Beauregard JM, Pouliot F. New developments in the imaging of metastatic prostate cancer. Current Opinion in Supportive and Palliative Care. 8: 265-70. PMID 25004180 DOI: 10.1097/Spc.0000000000000076 |
0.412 |
|
| 2013 |
Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer Journal (Sudbury, Mass.). 19: 189-96. PMID 23708063 DOI: 10.1097/Ppo.0B013E318292E8A4 |
0.353 |
|
| 2013 |
Pouliot F, Sato M, Jiang ZK, Huyn S, Karanikolas BD, Wu L. A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 554-60. PMID 23247102 DOI: 10.1038/Mt.2012.259 |
0.309 |
|
| 2013 |
Blouin A, Rimac G, Bouchard F, Lemay C, Fradet V, Caron A, Fradet Y, Lacombe L, Dujardin T, Tigert R, Beauregard J, Pouliot F. 241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.1621 |
0.358 |
|
| 2012 |
Rampersaud EN, Birkhauser F, Logan JE, Sonn G, Chan Y, Anterasian C, Li D, Pouliot F, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Non-clear cell histology in patients with metastatic RCC as a prognostic indicator in the targeted therapy era. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 454. PMID 27967914 DOI: 10.1200/Jco.2012.30.5_Suppl.454 |
0.353 |
|
| 2012 |
Imbeault A, Pouliot F, Finley DS, Shuch B, Dujardin T. Prospective study comparing two techniques of renal clamping in laparoscopic partial nephrectomy: impact on perioperative parameters. Journal of Endourology / Endourological Society. 26: 509-14. PMID 21823983 DOI: 10.1089/End.2011.0088 |
0.319 |
|
| 2012 |
Rampersaud EN, Birkhauser FD, Logan JE, Sonn G, Chan Y, Pouliot F, Wang X, Li G, Kabbinavar F, Pantuck AJ, Belldegrun AS. 2003 Antitumor Activity Of Sunitinib Versus Other Fda-Approved Targeted Cancer Agents Against Metastatic Renal Cell Carcinoma In The First-Line Setting The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.2165 |
0.391 |
|
| 2011 |
Mauermann J, Pouliot F, Fradet V. Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers. World Review of Nutrition and Dietetics. 102: 156-71. PMID 21865830 DOI: 10.1159/000327805 |
0.352 |
|
| 2011 |
Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. Basic research in kidney cancer. European Urology. 60: 622-33. PMID 21741760 DOI: 10.1016/J.Eururo.2011.06.048 |
0.382 |
|
| 2011 |
Pouliot F, Karanikolas BD, Johnson M, Sato M, Priceman SJ, Stout D, Sohn J, Satyamurthy N, deKernion JB, Wu L. In vivo imaging of intraprostatic-specific gene transcription by PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 784-91. PMID 21498525 DOI: 10.2967/Jnumed.110.084582 |
0.38 |
|
| 2011 |
Pouliot F, Pantuck A, Imbeault A, Shuch B, Calimlim B, Audet JF, Finley DS, Dujardin T. Multivariate analysis of the factors involved in loss of renal differential function after laparoscopic partial nephrectomy: a role for warm ischemia time. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 5: 89-95. PMID 21470531 DOI: 10.5489/Cuaj.10044 |
0.304 |
|
| 2011 |
Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun AS. Ultrasound-based combination therapy: potential in urologic cancer. Expert Review of Anticancer Therapy. 11: 107-13. PMID 21166515 DOI: 10.1586/Era.10.174 |
0.338 |
|
| 2011 |
Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. Bju International. 108: 343-8. PMID 21087450 DOI: 10.1111/J.1464-410X.2010.09871.X |
0.384 |
|
| 2011 |
Shuch B, Crispen PL, Leibovich BC, Larochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? Bju International. 107: 724-8. PMID 20626391 DOI: 10.1111/J.1464-410X.2010.09488.X |
0.333 |
|
| 2011 |
Rampersaud E, Klatte T, Pouliot F, Li D, Anterasian C, Zomorodian N, Kabbinavar F, Miller D, Belldegrun A, Pantuck A. 1770 Cancer-Specific Survival Outcomes Of Sunitinib Treatment In Uiss Risk-Stratified Metastatic Rcc Patients The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.2098 |
0.35 |
|
| 2010 |
Finley DS, Pouliot F, Pantuck A. Words of wisdom. Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. European Urology. 58: 466. PMID 20845530 DOI: 10.1016/J.Eururo.2010.06.020 |
0.337 |
|
| 2010 |
Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS. Contemporary management of renal tumors with venous tumor thrombus. The Journal of Urology. 184: 833-41; quiz 1235. PMID 20643450 DOI: 10.1016/J.Juro.2010.04.071 |
0.315 |
|
| 2010 |
Finley DS, Pouliot F, Miller DC, Belldegrun AS. Primary and salvage cryotherapy for prostate cancer. The Urologic Clinics of North America. 37: 67-82, Table of Cont. PMID 20152521 DOI: 10.1016/J.Ucl.2009.11.007 |
0.373 |
|
| 2010 |
Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. 116: 616-24. PMID 19998348 DOI: 10.1002/Cncr.24768 |
0.326 |
|
| 2010 |
Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De La Taille A, ... ... Pouliot F, et al. Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery European Urology. 57: 466-473. PMID 19359089 DOI: 10.1016/J.Eururo.2009.03.048 |
0.339 |
|
| 2010 |
Pouliot F, Anterasian C, Klatte T, Finley D, Shuch B, Kabbinavar FF, Zomorodian N, Belldegrun AS, Pantuck AJ. Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 28: 4593-4593. DOI: 10.1200/Jco.2010.28.15_Suppl.4593 |
0.342 |
|
| 2010 |
Pouliot F, Sato M, Johnson M, Huyn S, Karanikolas B, Wu L. 2152 A DUAL ADENOVIRAL AMPLIFICATION SYSTEM BASED ON PSA-PROMOTER TO INCREASE SENSITIVITY OF DETECTION OF PROSTATE CANCER CELLS IN VIVO BY NON INVASIVE IMAGING Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.2254 |
0.392 |
|
| 2010 |
Pouliot F, Anterasian C, Li Z, Shuch B, Calimlim B, Pantuck A, Belldegrun A. 1792 Validation Of Ca-Ix Polymorphism Rs12553173 As An Independent Prognostic Factor Of Overall Survival In Metastatic Clear Cell Renal Cell Carcinoma The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1716 |
0.304 |
|
| 2009 |
Pouliot F, Pantuck AJ. Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial. European Urology. 55: 1482-4. PMID 19650239 DOI: 10.1016/J.Eururo.2009.03.034 |
0.331 |
|
| 2009 |
Pouliot F, Johnson M, Wu L. Non-invasive molecular imaging of prostate cancer lymph node metastasis. Trends in Molecular Medicine. 15: 254-62. PMID 19482514 DOI: 10.1016/J.Molmed.2009.04.004 |
0.339 |
|
| 2009 |
Pouliot F, Pantuck AJ, Belldegrun AS, Dujardin T. Effect Of Warm Ischemia Time On Renal Differential Renal Function After Renal Artery Clamping For Laparoscopic Partial Nephrectomy The Journal of Urology. 181: 277-277. DOI: 10.1016/S0022-5347(09)60787-4 |
0.322 |
|
| 2006 |
Pouliot F, Larue H, Girard J, Hovington H, Fradet Y. 612: Alterations of the Sonic Hedgehog Pathway in Human Superficial Bladder Cancer: Loss of PTC and GLI Expression Journal of Urology. 175: 197-198. DOI: 10.1016/S0022-5347(18)32858-1 |
0.322 |
|
| 2003 |
Pouliot F, Blais A, Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Research. 63: 277-81. PMID 12543773 |
0.561 |
|
| 2002 |
Blais A, Monté D, Pouliot F, Labrie C. Regulation of the human cyclin-dependent kinase inhibitor p18INK4c by the transcription factors E2F1 and Sp1. The Journal of Biological Chemistry. 277: 31679-93. PMID 12077144 DOI: 10.1074/Jbc.M204554200 |
0.537 |
|
| 2002 |
Pouliot F, Labrie C. Role of Smad1 and Smad4 proteins in the induction of p21WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. The Journal of Endocrinology. 172: 187-98. PMID 11786386 DOI: 10.1677/Joe.0.1720187 |
0.593 |
|
| 1999 |
Pouliot F, Labrie C. Expression profile of agonistic Smads in human breast cancer cells: absence of regulation by estrogens. International Journal of Cancer. 81: 98-103. PMID 10077159 DOI: 10.1002/(Sici)1097-0215(19990331)81:1<98::Aid-Ijc17>3.0.Co;2-9 |
0.571 |
|
| 1998 |
Blais A, Labrie Y, Pouliot F, Lachance Y, Labrie C. Structure of the gene encoding the human cyclin-dependent kinase inhibitor p18 and mutational analysis in breast cancer. Biochemical and Biophysical Research Communications. 247: 146-53. PMID 9636670 DOI: 10.1006/Bbrc.1998.8497 |
0.571 |
|
| 1998 |
Couillard S, Labrie C, Bélanger A, Candas B, Pouliot F, Labrie F. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. Journal of the National Cancer Institute. 90: 772-8. PMID 9605648 DOI: 10.1093/Jnci/90.10.772 |
0.711 |
|
| Show low-probability matches. |